Pages

Saturday, January 21, 2012

New Device May Collect Blood Painlessly.

The Boston Globe Share to FacebookShare to Twitter (1/3, Pierce) reports on "TAP, for Touch Activated Phlebotomy," a new, portable device by Seventh Sense that "adheres to skin" and uses "16 tiny needles" to penetrate skin in order "to collect blood." The device "is designed to be painless and compact" and "will be tested in hospitals in March. ... TAP collects more blood than a finger stick and less than a typical needle -- but enough to perform a range of diagnostic tests, from routine kidney function to infectious diseases, such as HIV and hepatitis."

New CMS Project To Manage Chronic Illnesses With Home Care.

Healthcare IT News Share to FacebookShare to Twitter (12/31, Monegain) reported, "Up to 10,000 Medicare patients with chronic conditions will be able to get most of the care they need at home under a new demonstration project developed by the Centers for Medicare & Medicaid Services (CMS)." The CMS definition of home practice is "one that 'uses electronic health information systems, remote monitoring, and mobile diagnostic technology.'" The piece added, "Created by the Affordable Care Act, the new Independence at Home Demonstration greatly expands the scope of in-home services Medicare beneficiaries can receive. The Independence at Home Demonstration will provide chronically ill patients with a complete range of primary care services." Participation is strictly voluntary.

NYTimes Argues For Eventual National Standard For "Essential Health Benefits."

The New York Times Share to FacebookShare to Twitter (1/2, A20, Subscription Publication) editorializes on the administration's move "to let states define the 'essential health benefits' that must be provided to their citizens under health care reform," arguing that it "could lessen opposition in Republican-led states and increase the chances that they will move ahead on building new health insurance exchanges to comply with the reform law." Noting that "Secretary Kathleen Sebelius has passed those decisions to the states, at least for a two-year transition period in 2014 and 2015," the Times concludes that "federal health officials will need to monitor developments during the transition period to make sure consumers and employers can easily compare the benefit packages offered by private insurers." According to the Times, "In the longer run, it would be better to set a national standard."

Urinalysis May Provide Clues To Medical Problems.

In "Personal Health," the New York Times Share to FacebookShare to Twitter (1/3, D7, Brody, Subscription Publication) discusses urinalysis, noting that "the color, clarity and other physical characteristics of urine, as well as substances dissolved in it, can provide clues to a wide range of problems, including infections, inherited metabolic disorders, kidney disease, bladder cancer, diabetes, substance abuse, exposure to toxins, inadequate or excessive fluid intake and, as many competing athletes know all too well, the use of performance-enhancing drugs."

Rise In Resting Heart Rate Linked To Increased Risk Of Death From Coronary Artery Disease.

The New York Times Share to FacebookShare to Twitter (1/3, D6, Bakalar, Subscription Publication) reports, "A large study Share to FacebookShare to Twitter has found that a rise in resting heart rate over a decade may indicate an increased risk of death from coronary artery disease." Investigators "studied 30,000 healthy men and women age 20 and older, checking heart rates at intervals 10 years apart. The scientists followed the subjects through 2008, recording the number of deaths from coronary heart disease." Researchers found that, "compared with those whose heart rates remained stable at 70 beats per minute or less, those whose rates increased to 85 or more were almost twice as likely to die of heart disease." The research is published in the Journal of the American Medical Association.

Unnecessary Heart Screening Tests May Lead To Unnecessary Treatments.

According to a Washington Post Share to FacebookShare to Twitter /Consumer Reports (1/3) article, one "might assume...that even if you have no symptoms," cardiac screening "tests are still helpful because they will either reassure you or alert you to conditions you weren't aware of." The Post points out, however, that "a stress test with normal results can create a false sense of security, which might cause you to relax your healthful habits," while "an abnormal test might cause unnecessary worry and depression," or even "invasive and potentially harmful testing and treatment."

Nocturnal Hemodialysis Should We Still Provide This Therapy?

Medscape Link
Peter G. Kerr
Posted: 11/27/2011; Nat Rev Nephrol. 2011;7(11):611-612. © 2011 Nature Publishing Group


Abstract and Introduction

Abstract

Frequent nocturnal hemodialysis has emerged as a promising option for patients, with some studies demonstrating that it improves clinical outcomes. However, the negative results of a recent randomized trial have cast some doubt on whether nocturnal home hemodialysis has any advantages over conventional hemodialysis.

Introduction

The Frequent Hemodialysis Network (FHN) has recently published the results of their trial comparing frequent nocturnal hemodialysis with conventional hemodialysis.[1] This trial has been reported as 'negative' as the investigators were unable to report a positive benefit of nocturnal hemodialysis (six sessions per week) over conventional hemodialysis (three times per week) according to their prespecified composite end point of death, left ventricular hypertrophy and physical well-being. These results are disappointing as enthusiasm for nocturnal hemodialysis schedules has been growing in several centers around the world. Marked anecdotal improvements in patient well-being have been reported, and most clinicians are struck by the apparent benefits when patients are switched to this modality.[2] However, very little data from controlled trials have been published to support these observations.
The investigators of the FHN trial initially set out to enroll 250 patients, although recruitment difficulties meant that only 87 patients were randomly assigned to conventional or nocturnal hemodialysis. At 12 months, left ventricular mass data were available for only 76 patients. Only three deaths occurred during the follow-up period. Patients receiving nocturnal hemodialysis had an adjusted mean reduction in left ventricular mass of 10.9 g (95% CI −23.7 to +1.8 g; P = 0.095) with no appreciable difference in the physical health composite score (both groups demonstrated improvement over the 12 months). Although the change in left ventricular mass was not significant, the authors reflect that changes in left ventricular mass of a similar size have been associated with improvements in mortality of up to 50% in other studies. Significant improvements were seen in two clinically important prespecified outcomes—hypertension and hyperphosphatemia—among patients receiving nocturnal dialysis, which are factors that could be expected to impact on mortality in the long term.
There is little doubt that the trial was underpowered. By enrolling 90 patients there was an 80% chance of detecting a significant 19.6 g reduction in left ventricular mass and a 7.4 point improvement in the physical health composite score. For a 10 g difference in left ventricular mass, 275 patients would have been required to obtain 80% power. It is worth noting that the left ventricular mass effect size was not markedly dissimilar to that in the FHN frequent (short daily) trial,[3] or the nocturnal hemodialysis trial carried out by Culleton and colleagues, which is the only other randomized, controlled trial to compare nocturnal hemodialysis with conventional hemodialysis.[4] Both of these trials reached significance for the outcome of change in left ventricular mass. More patients or a longer follow-up might have resulted in a positive outcome for the FHN trial, although this possibility remains speculation.
The power of the study is not the only issue to consider. The amount of dialysis delivered is also somewhat problematic. Firstly, the conventional arm received about 45 min more dialysis per session than the US average (256 min compared with the usual 213 min),[5] whereas the nocturnal group received 30 h per week (as a session duration minimum of 6 h was stipulated), which is less than the more commonly used 8 h sessions for this modality (providing >40 h per week). Secondly, only 72.7% of patients completed the required number of dialysis sessions in the nocturnal arm. These factors meant that there was less difference in delivered dialysis hours than might have been expected between the conventional and nocturnal arms, with less likelihood for differential effects to become apparent. A high level of noncompliance with the regimen also raises the possibility of noncompliance with other aspects of the treatment, such as volume control, phosphate control and medication usage. Finally, higher weekly average weight gains were seen in the nocturnal group than in the conventional group, which is a commonly reported phenomenon explained by improved well-being and better appetite. These volume changes may have impacted on volume loading, left ventricular dilatation and subsequently left ventricular mass.[6]
Despite the weight gains, the investigators reported improved blood pressure control, which has been widely reported previously for nocturnal hemodialysis cohorts. The ideal blood pressure for patients on hemodialysis is not well defined. Whether normal blood pressure targets used in the general population are associated with the best outcomes in patients on hemodialysis is disputed. Observational, but short-term, data suggest the best survival outcomes are associated with systolic blood pressure readings of 140–160 mmHg.[7] However, longer-term data are more suggestive that blood pressure targets in the general population are more appropriate for patients on dialysis. Phosphate control is significantly associated with mortality in large observational studies of patients on hemodialysis, again with little data from randomized, controlled studies to confirm this observation.[8] Most groups reporting nocturnal hemodialysis patient cohorts have commented on the marked improvement in phosphate control with this modality, with most patients not requiring phosphate binders and some even requiring phosphate supplementation. However, perhaps as seen in the FHN nocturnal trial, translating this potential benefit into improved survival in a randomized, controlled trial setting has not yet been achieved.
Can we say that nocturnal hemodialysis at least does no harm? The main concern from this FHN trial was the trend to more vascular access complications in the nocturnal arm. Again, this result did not reach statistical significance, but was it clinically significant? Importantly, 45% of patients used catheters to dialyze at home, a statistic that most home dialysis units would find unusually high. Furthermore, 44% of the vascular access events occurred in patients with catheters, which reduces the number of events that units might expect to see in more typical patients with permanent access. The use of buttonholing was nearly twice as common in the nocturnal group, which is a practice identified by some as being associated with a significantly increased rate of access infection and complications.[9] Avoidance of buttonholing in the home setting might therefore be appropriate.
Finally, how much benefit is simply a result of having dialysis at home? This point was raised by the investigators, particularly in relation to the physical health composite score. Patients who receive home hemodialysis tend to be more enthusiastic about participating in their own care and are empowered to do so and are a self-selected group. Although large observational studies have repeatedly demonstrated improved survival for patients on home hemodialysis, eliminating the biases associated with these analyses is difficult.[10] Interestingly, a recent ANZDATA analysis also showed no benefit of extended-hours dialysis (at home) compared with conventional home hemodialysis.[10]
Although the FHN trial by Rocco et al. is technically a negative trial, it is unlikely to deter nocturnal hemodialysis enthusiasts from their path. The trial may be dismissed as underpowered, which is possibly the correct interpretation, but we should be encouraged that home hemodialysis is a safe and effective treatment. Looking to the longer term, we should also be encouraged by the improved blood pressure and phosphate control. Whether we will ever see a large enough randomized, controlled trial of nocturnal versus conventional hemodialysis to answer the question of mortality as an outcome is doubtful.

More specifics on this article can be found here:
Medscape Article Details